JCR Pharmaceuticals Co., Ltd.

4552

JP3701000006

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
793 ^JPY	-2.46%		-1.00%	-32.34%

Mar. 21	US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	MT
Mar. 21	JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion	MT

JCR Pharmaceuticals : Japan to agree supply deal soon for AstraZeneca's coronavirus vaccine - Kyodo

August 06, 2020 at 09:50 pm EDT

The Japanese government will soon agree a supply deal for more than 100 million doses of a coronavirus vaccine being developed by AstraZeneca Plc, Kyodo news agency reported on Friday.

The British drugmaker has been in talks with Japan, Russia, Brazil and others about supply deals for its potential coronavirus vaccine, known as AZD1222.

(Reporting by Chang-Ran Kim; Editing by Muralikumar Anantharaman)

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ASTRAZENECA PLC	12,026 GBX	+5.94%	+10.19%	219B
DAIICHI SANKYO CO., LTD.	4,766 JPY	+0.78%	+7.27%	58.47B
US DOLLAR / RUSSIAN ROUBLE	91.98 RUB	-0.35%	-2.21%	-
EURO / BRAZILIAN REAL	5.542 BRL	+0.66%	-0.95%	-

Latest news about JCR Pharmaceuticals Co., Ltd.

US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	Mar. 21	MT
JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion	Mar. 20	MT
JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion	Mar. 19	CI
JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index	Mar. 17	CI
Mycenax Biotech Inc. announced that it expects to receive funding from Center Laboratories, Inc., JCR Pharmaceuticals Co., Ltd., Taiwan BioVenture Company, Jason Technologies Ltd	Mar. 12	CI
JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes	Feb. 28	CI
JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier	Feb. 14	CI
JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Feb. 08	CI
Asia Markets Remain Mixed as Investors Step Back Following Rally	Dec. 21	MT
Japanese Shares Slip Back into Red as Wall Street Ends Winning Streak Ahead of Key US Data	Dec. 21	MT
JCR Pharmaceuticals' Partner Takeda to Scrap Gene Therapy Collaboration	Dec. 21	MT
JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Announces Discontinuation of Gene Therapy Collaboration	Dec. 20	CI
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo	Dec. 20	CI
JCR Pharmaceuticals' Metabolic Disease Drug Candidate Granted FDA's Orphan Drug Designation	Dec. 14	MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	Dec. 12	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	Dec. 12	CI
Japanese Shares Rebound on Wednesday, Boosted by Automotive Stocks	Nov. 22	MT
JCR Pharmaceuticals' Fiscal H1 Attributable Profit Climbs on Increased Drug Sales	Nov. 21	MT
JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA	23-10-26	CI
Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 1,200 Yen From 1,400 Yen, Keeps at Hold	23-10-26	MT
JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	23-10-25	CI
Jefferies Adjusts JCR Pharmaceuticals’ Price Target to 1,400 Yen From 1,360 Yen, Keeps at Hold	23-10-05	MT
JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)	23-09-29	CI
MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Conclude Two Agreements on Mucopolysaccharidosis Type IIIB Treatment	23-09-28	CI
JCR Pharmaceuticals Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-09-28	CI

Chart JCR Pharmaceuticals Co., Ltd.

Duration

Period

More charts

JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Company operates in two segments. The Pharmaceutical segment engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment segment engages in the purchase and sale of the medical and research equipment.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for JCR Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

793 JPY

Average target price

1,557 JPY

Spread / Average Target

+96.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JCR PHARMACEUTICALS CO., LTD.	-32.34%	654M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.59%	358B
MERCK & CO., INC.	+19.26%	322B
ABBVIE INC.	+7.82%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.53%	149B
AMGEN INC.	-6.83%	146B

Other Pharmaceuticals

JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Pharmaceuticals

JCR Pharmaceuticals : Japan to agree supply deal soon for AstraZeneca's coronavirus vaccine - Kyodo

Stocks mentioned in the article

Latest news about JCR Pharmaceuticals Co., Ltd.

Chart JCR Pharmaceuticals Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for JCR Pharmaceuticals Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals